ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections
Transplant Infectious Disease · 2026
DOI: 10.1111/tid.70237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Milo Gatti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Liver Transplantation, Anti-Bacterial Agents, beta-Lactams, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Background
To assess the true prevalence and the risk factors of augmented renal clearance (ARC) in critical orthotopic liver transplant (OLT) recipients and its impact on early aggressive pharmacokinetic/pharmacodynamic (PK/PD) target non‐attainment of continuous infusion (CI) beta‐lactams.
Methods
OLT recipients without renal dysfunction and undergoing one or more measured creatinine clearance (mCLCr) assessments in the first 30 days posttransplant were retrospectively included. Reliability of three different eGFR formulas (Cockcroft–Gault, 2021, CKD‐EPI, and MDRD) in estimating mCLCr was tested. Univariate analyses compared the clinical features of ARC versus non‐ARC patients and the severity of the clinical conditions during ARC versus non‐ARC episodes in the whole cohort. In patients receiving CI beta‐lactam therapy, risk factors for early aggressive PK/PD target non‐attainment were investigated.
Results
Among 450 critical OLT recipients, 112 were included. The true prevalence of ARC was 23.2%. ARC versus non‐ARC patients were younger ( p = 0.003), had lower MELD score ( p = 0.001), received lower number of intraoperative blood transfusions ( p = 0.007), and had a lower need for venovenous bypass technique ( p = 0.024). ARC episodes occurred more frequently in patients having lower SOFA score ( p = 0.005) and lower median serum creatinine levels ( p < 0.001). None of the eGFR formulas properly estimated mCLCr. In the subset of 50 OLT recipients receiving 60 CI beta‐lactam treatment courses, ARC was the only factor associated with early aggressive PK/PD target non‐attainment ( p = 0.018).
Conclusions
ARC is a quite prevalent condition among critical OLT recipients, which may hinder early aggressive PK/PD target attainment when using standard beta‐lactams dosing regimens, regardless of delivery by CI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Specialization School of Clinical Pharmacology and Toxicology, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Anesthesia and Intensive Care Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
ORCID-Profile: Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Förderung
- Italian Ministry of Health
Zitieren
APA
Gatti, M., De Paola, R., Rinaldi, M., Laici, C., Siniscalchi, A., Viale, P., & Pea, F. (2026). ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections. Transplant Infectious Disease. https://doi.org/10.1111/tid.70237
Vancouver
Gatti M, De Paola R, Rinaldi M, Laici C, Siniscalchi A, Viale P, et al. ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections. Transplant Infectious Disease. 2026. doi:10.1111/tid.70237
BibTeX
@article{Gatti2026,
author = {Gatti, Milo and De Paola, Riccardo and Rinaldi, Matteo and Laici, Cristiana and Siniscalchi, Antonio and Viale, Pierluigi and Pea, Federico},
title = {ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections},
journal = {Transplant Infectious Disease},
year = {2026},
doi = {10.1111/tid.70237}
}
EUVIMED